OUR PIPELINE

A Multi-pronged Therapeutic Strategy

Chromosomal instability (CIN) is one of cancer’s most targetable vulnerabilities. Our understanding of the underlying biological mechanisms of CIN has revealed processes within CIN-high cancer cells previously under-appreciated in oncology drug discovery. Volastra is progressing a pipeline of owned and partnered programs targeting various CIN related pathways.

We are initially focusing our efforts on two therapeutic approaches: Synthetic lethality and Immune Activation. Our end goal? To stop cancer in its tracks.

Program
Therapeutic Approach
Discovery
Lead Optimization
IND Enabling
K1F18A
Synthetic Lethal
CRISPR hits
Synthetic Lethal
Undisclosed
Synthetic Lethal
Undisclosed
Immune Activation
Type 1 interferon CRISPR screen
Immune Activation
Undisclosed
Immune Activation